OFI Invest Asset Management Takes $34,000 Position in The Cooper Companies, Inc. (NASDAQ:COO)

OFI Invest Asset Management bought a new stake in The Cooper Companies, Inc. (NASDAQ:COO) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 386 shares of the medical device company’s stock, valued at approximately $34,000.

A number of other large investors have also modified their holdings of the company. Rialto Wealth Management LLC acquired a new position in shares of Cooper Companies in the fourth quarter valued at $215,000. Machina Capital S.A.S. raised its stake in shares of Cooper Companies by 363.5% in the fourth quarter. Machina Capital S.A.S. now owns 16,936 shares of the medical device company’s stock valued at $1,557,000 after purchasing an additional 13,282 shares in the last quarter. Andra AP fonden acquired a new position in shares of Cooper Companies in the fourth quarter valued at $1,030,000. Callan Family Office LLC acquired a new position in shares of Cooper Companies in the fourth quarter valued at $381,000. Finally, E Fund Management Co. Ltd. raised its stake in shares of Cooper Companies by 98.2% in the fourth quarter. E Fund Management Co. Ltd. now owns 3,791 shares of the medical device company’s stock valued at $349,000 after purchasing an additional 1,878 shares in the last quarter. 24.39% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

COO has been the subject of a number of recent research reports. Robert W. Baird cut their target price on Cooper Companies from $117.00 to $107.00 and set an “outperform” rating for the company in a research note on Friday. Piper Sandler reiterated an “overweight” rating and set a $115.00 price objective (down from $120.00) on shares of Cooper Companies in a research note on Friday. JPMorgan Chase & Co. dropped their price objective on Cooper Companies from $120.00 to $110.00 and set an “overweight” rating for the company in a research note on Friday. Wells Fargo & Company increased their price objective on Cooper Companies from $115.00 to $118.00 and gave the stock an “overweight” rating in a research note on Friday, December 6th. Finally, StockNews.com lowered Cooper Companies from a “buy” rating to a “hold” rating in a research note on Wednesday, December 11th. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, Cooper Companies currently has a consensus rating of “Moderate Buy” and a consensus target price of $111.89.

Cooper Companies Stock Performance

Shares of NASDAQ:COO opened at $79.89 on Tuesday. The Cooper Companies, Inc. has a twelve month low of $79.74 and a twelve month high of $112.38. The firm has a market cap of $15.94 billion, a PE ratio of 40.97, a price-to-earnings-growth ratio of 2.25 and a beta of 1.02. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.12 and a current ratio of 1.91. The business has a fifty day moving average of $92.14 and a 200-day moving average of $99.34.

Cooper Companies (NASDAQ:COO) last announced its earnings results on Thursday, March 6th. The medical device company reported $0.92 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.92. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. The company had revenue of $964.70 million during the quarter, compared to analyst estimates of $981.25 million. On average, equities research analysts predict that The Cooper Companies, Inc. will post 3.98 EPS for the current fiscal year.

Cooper Companies Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.